Key Highlights
- Adam Perlman, MD, MPH, FACP, joins Pendulum Therapeutics as Chief Medical Officer, bringing over 25 years of expertise in integrative and functional medicine.
- Dr. Perlman to lead clinical research portfolio, focusing on microbiome science and health, and development of new products targeting metabolic health.
- Successfully initiated a clinical trial on Pendulum Glucose Control (PGC) at Mayo Clinic, demonstrating his commitment to evidence-based approaches in metabolic health.
Source: Business Wire
Notable Quote
- “It is critical to educate people on how a targeted approach to a healthy gut microbiome can positively affect overall health and wellbeing to help them improve vitality and live their best lives,” – Adam Perlman, Chief Medical Officer at Pendulum Therapeutics
SoH's Take
The addition of Dr. Adam Perlman to Pendulum Therapeutics represents a significant leap in the field of metabolic health and microbiome research. His vast experience in integrative and functional medicine, coupled with his recent achievements in clinical research, positions Pendulum to pioneer innovative solutions in this space. Dr. Perlman’s move to Pendulum also underscores a growing trend in healthcare – the shift towards preventive and holistic approaches, particularly in managing chronic diseases like diabetes. His hands-on experience with Pendulum products in clinical settings lends credibility and promises to bring real-world insights into product development. As the industry observes a surge in consumer interest towards personalized and gut health-focused therapies, Pendulum, under Dr. Perlman’s medical leadership, is well-equipped to lead the charge in translating cutting-edge microbiome research into practical, consumer-friendly health solutions.
